Caris Life Sciences (CAI) Receivables (2024 - 2026)

Caris Life Sciences' Receivables history runs 3 years deep, the most recent figure standing at $94.2 million for Q1 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $94.2 million in Q1 2026; TTM through Mar 2026 was $94.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $119.3 million, up 28.54% from the prior year.
• Receivables retreated to $94.2 million in Q1 2026 per CAI's latest filing, from $119.3 million in the prior quarter.
• Across five years, Receivables topped out at $119.3 million in Q4 2025 and bottomed at $36.6 million in Q3 2025.
• The 3-year median for Receivables is $92.8 million (2024), against an average of $81.0 million.
• Biggest YoY gain for Receivables was 28.54% in 2025; the steepest drop was 28.54% in 2025.
• Year by year, Receivables stood at $92.8 million in 2024, then increased by 28.54% to $119.3 million in 2025, then retreated by 21.05% to $94.2 million in 2026.
• Per Business Quant, the three latest CAI Receivables figures stand at $94.2 million (Q1 2026), $119.3 million (Q4 2025), and $36.6 million (Q3 2025).